title: Chemotherapy of respiratory syncytial virus infections: the final breakthrough.
abstract: Respiratory syncytial virus (RSV) infection is the leading cause of hospitalisation for children under 5 years of age and causes excess mortality in the elderly. There is still no approved vaccine available, although the disease can be curtailed by RSV-specific monoclonal antibody. The only antiviral drug approved for the treatment of RSV infection is ribavirin aerosol, but this treatment is cumbersome and its efficacy is questionable. A new antiviral, GS-5806, which interferes with virus-cell fusion, has proven efficacious in experimental RSV infections in adults.
authors: Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Electronic address: erik.declercq@rega.kuleuven.be.
authors: Erik
authors: E
authors: De Clercq
mesh_terms: D000280:Administration, Inhalation; D000998:Antiviral Agents / Q000627:therapeutic use*; D006801:Humans; D007191:Indazoles; D011720:Pyrazoles / Q000627:therapeutic use; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy*; D012254:Ribavirin / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D007191:Indazoles; D011720:Pyrazoles; D013449:Sulfonamides; D012254:Ribavirin; C000591241:presatovir
keywords: GS-5806; Palivizumab; RSV; Respiratory syncytial virus; Ribavirin; Virus–cell fusion